1. Home
  2. INKT vs BOLD Comparison

INKT vs BOLD Comparison

Compare INKT & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MiNK Therapeutics Inc.

INKT

MiNK Therapeutics Inc.

N/A

Current Price

$8.61

Market Cap

53.7M

Sector

Health Care

ML Signal

N/A

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

N/A

Current Price

$2.35

Market Cap

54.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
INKT
BOLD
Founded
2017
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.7M
54.5M
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
INKT
BOLD
Price
$8.61
$2.35
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
★ $44.00
N/A
AVG Volume (30 Days)
10.2K
★ 77.7K
Earning Date
11-11-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 32.47
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.48
$0.96
52 Week High
$15.27
$3.16

Technical Indicators

Market Signals
Indicator
INKT
BOLD
Relative Strength Index (RSI) 33.82 40.28
Support Level N/A $2.32
Resistance Level $11.92 $2.62
Average True Range (ATR) 0.73 0.09
MACD -0.12 0.00
Stochastic Oscillator 10.85 10.10

Price Performance

Historical Comparison
INKT
BOLD

About INKT MiNK Therapeutics Inc.

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: